Dictyota menstrualis (Hoyt) Schnetter, Hörning & Weber-Peukert (Dictyotales, Phaeophyceae) was studied for the manufacturing of oil-based bioproducts and co-products. Experiments have been carried out to judge the impact of carbon dioxide (CO2) focus, beneath nitrogen (NO3 (-)) limiting and saturation situations, on progress fee (GR), photosynthesis, in addition to nitrate reductase (NR), carbonic anhydrase (CA), and Rubisco actions. As well as, the biochemical composition of D. menstrualis beneath these situations was estimated. GR, protein content material, and N content material in D. menstrualis have been increased in therapies containing NO3 (-), no matter CO2 addition.
Nonetheless, when CO2 was added to medium saturated with NO3 (-), values of most photosynthesis, Rubisco, and NR exercise, in addition to whole soluble carbohydrates and lipids, have been elevated. CA exercise didn’t range beneath the completely different therapies. The fatty acid profile of D. menstrualis was characterised by a excessive content material of polyunsaturated fatty acids, particularly the omega-Three fatty acids, making it a doable candidate for nutraceutical use.
As well as, this species introduced excessive GR, photosynthetic fee, and fatty acid content material, highlighting its financial significance and the potential for completely different biotechnological functions. High quality and security of perishable merchandise reminiscent of meals, pharmaceutics, and biologicals is a continuing concern. Now we have developed a plasmonic thermal historical past indicator (THI) making the most of the localized floor plasmon resonance of gold nanoparticles (AuNPs) synthesized in situ in alginate, a pure polysaccharide. The colour of the THIs turns into extra intense with elevated storage temperature and/or length, with the colour altering from gray to purple with time of publicity at excessive temperature (40°C).
The outcomes counsel that reducing viscosity with rising variety of AuNPs being synthesized within the system, together with aggregation of newly synthesized AuNPs onto bigger ones and their settling are doubtlessly chargeable for the distinct shade change noticed. Using alginate within the THIs additionally facilitates fabricating them as strong hydrogel matrices by including divalent calcium ions. This alginate-AuNPs THI system is tunable by altering its composition to swimsuit completely different time-temperature monitoring eventualities and the color-change response is irreversible. The THI offers a handy, dependable, secure, and cheap means for monitoring the thermal historical past of perishable merchandise with out the necessity for a read-out gadget.
Ionic liquid-tolerant microorganisms and microbial communities for lignocellulose conversion to bioproducts.
Chemical and bodily pretreatment of biomass is a crucial step within the conversion of lignocellulose to biofuels and bioproducts. Ionic liquid (IL) pretreatment has attracted important consideration as a result of distinctive means of sure ILs to solubilize some or all parts of the plant cell wall. Nonetheless, these ILs inhibit not solely the enzyme actions but in addition the expansion and productiveness of microorganisms utilized in downstream hydrolysis and fermentation processes.
Whereas pretreated biomass could be washed to take away residual IL and cut back inhibition, in depth washing is dear and never possible in large-scale processes. IL-tolerant microorganisms and microbial communities have been found from environmental samples and research begun to elucidate mechanisms of IL tolerance. The invention of IL tolerance in environmental microbial communities and particular person microbes has result in the proposal of molecular mechanisms of resistance. On this article, we assessment latest progress on discovering IL-tolerant microorganisms, figuring out metabolic pathways and mechanisms of tolerance, and engineering microorganisms for IL tolerance. Analysis in these areas will yield new approaches to beat inhibition in lignocellulosic biomass bioconversion processes and improve alternatives for the usage of ILs in biomass pretreatment.
Municipal wastes, be it strong or liquid, are rising as a result of world inhabitants progress and speedy urbanization and industrialization. Typical administration apply involving recycling, combustion, and therapy/disposal is deemed unsustainable. Options should be sought to not solely improve the capability but in addition enhance the sustainability of waste administration. Analysis has demonstrated that the non-recyclable waste supplies and bio-solids could be transformed into useable warmth, electrical energy, or gas and chemical by way of a wide range of processes, together with gasification, pyrolysis, anaerobic digestion, and landfill gasoline along with combustion, and wastewater streams have the potential to help algae progress and supply different vitality restoration choices.
The current assessment is meant to evaluate and analyze the present state of data within the municipal strong wastes and wastewater therapy and utilization applied sciences and suggest sensible resolution choices and future analysis and improvement wants.
Hydraulic retention time results on wastewater nutrient elimination and bioproduct manufacturing through rotating algal biofilm reactor.
Rotating algal biofilm reactor (RABR) know-how was efficiently employed in an efficient technique to couple the elimination of wastewater vitamins with accumulation of priceless bioproducts by grown algae. A secondary stage municipal wastewater was fed to the developed system and the results of the hydraulic retention time (HRT) parameter on each nutrient elimination and bioproduct manufacturing have been evaluated beneath fed-batch operation mode. Two units of bench scale RABRs have been designed and operated with HRTs of two and 6days in an effort to present aggressive atmosphere for algal progress.
VAP1 (AOC3) goat polyclonal antibody, Aff - Purified |
|||
AP32053PU-N | Origene Technologies GmbH | 100 µg | Ask for price |
AOC3 / VAP1 Peptide |
|||
43-199P | ProSci | 0.1 mg | EUR 405.6 |
VAP1 (AOC3) (712-724) goat polyclonal antibody, Aff - Purified |
|||
AP08978PU-N | Origene Technologies GmbH | 50 µg | Ask for price |
VAP1 (AOC3) mouse monoclonal antibody, clone 174-5, Purified |
|||
AM26204PU-N | Origene Technologies GmbH | 100 µg | Ask for price |
Anti-VAP1 antibody |
|||
PAab09368 | Lifescience Market | 100 ug | EUR 426 |
anti-VAP1 |
|||
YF-PA15759 | Abfrontier | 50 ug | EUR 435.6 |
Description: Mouse polyclonal to VAP1 |
Anti-VAP1 (4B8) |
|||
YF-MA16461 | Abfrontier | 100 ug | EUR 435.6 |
Description: Mouse monoclonal to VAP1 |
VAP-1 Antibody / AOC3 |
|||
F54455-0.08ML | NSJ Bioreagents | 0.08 ml | EUR 140.25 |
Description: Copper amine oxidases catalyze the oxidative conversion of amines to aldehydes in the presence of copper and quinone cofactor. The product is a major protein on the adipocyte plasma membrane. It has adhesive properties and also has functional monoamine oxidase activity. |
VAP-1 Antibody / AOC3 |
|||
F54455-0.4ML | NSJ Bioreagents | 0.4 ml | EUR 322.15 |
Description: Copper amine oxidases catalyze the oxidative conversion of amines to aldehydes in the presence of copper and quinone cofactor. The product is a major protein on the adipocyte plasma membrane. It has adhesive properties and also has functional monoamine oxidase activity. |
VAP-1 Antibody / AOC3 |
|||
R33999-100UG | NSJ Bioreagents | 100 ug | EUR 339.15 |
Description: Additional name(s) for this target protein: Vascular adhesion protein 1; AOC3 |
Anti-Human VAP-1 Antibody |
|||
102-P108 | ReliaTech | 100 µg | EUR 245.7 |
Description: VAP-1 is a type II membrane cell adhesion protein belonging to the copper/topaquinone oxidase family. It is primarily expressed on the high endothelial venules of peripheral lymph nodes and on hepatic endothelia. VAP-1 can catalyze the oxidative deamination of low molecular weight amines, and plays an important role in the migration of lymphocytes to inflamed tissue. Inhibition of VAP-1 can protect against inflammation-related damage to certain injured tissues. Additionally, VAP-1 can function as a significant prognostic marker for certain cancers and cardiovascular diseases. |
OAAV00163-200UG - VAP-1 Antibody |
|||
OAAV00163-200UG | Aviva Systems Biology | 200ug | EUR 459 |
OAAV00164-200UG - VAP-1 Antibody |
|||
OAAV00164-200UG | Aviva Systems Biology | 200ug | EUR 459 |
OAAV00165-200UG - VAP-1 Antibody |
|||
OAAV00165-200UG | Aviva Systems Biology | 200ug | EUR 459 |
OAAV00166-200UG - VAP-1 Antibody |
|||
OAAV00166-200UG | Aviva Systems Biology | 200ug | EUR 459 |
AOC3 Antibody / VAP-1 |
|||
R33411-100UG | NSJ Bioreagents | 100 ug | EUR 339.15 |
Description: Additional name(s) for this target protein: Amine oxidase, copper containing 3 |
Polyclonal AOC3 / VAP-1 Antibody (Internal) |
|||
AMRa00049G | Leading Biology | 0.05mg | EUR 580.8 |
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human AOC3 / VAP-1 (Internal). This antibody is tested and proven to work in the following applications: |
Vascular Adhesion Protein 1 (VAP-1) Antibody |
|||
20-abx225038 | Abbexa |
|
|
Antitoxin VapB (vapB) Antibody |
|||
abx345853-100l | Abbexa | 100 µl | EUR 350 |
Antitoxin VapB (vapB) Antibody |
|||
abx345853-50l | Abbexa | 50 µl | EUR 250 |
VAPB Antibody |
|||
ABD7303 | Lifescience Market | 100 ug | EUR 525.6 |
VAPA antibody |
|||
22585 | SAB | 100ul | EUR 479 |
VAPA antibody |
|||
22585-100ul | SAB | 100ul | EUR 468 |
VAPB Antibody |
|||
32803 | SAB | 100ul | EUR 439 |
VAPB Antibody |
|||
32803-100ul | SAB | 100ul | EUR 302.4 |
VAPA Antibody |
|||
42826 | SAB | 100ul | EUR 319 |
VAPA Antibody |
|||
42826-100ul | SAB | 100ul | EUR 302.4 |
VAPA Antibody |
|||
E042826 | EnoGene | 100μg/100μl | EUR 255 |
Description: Available in various conjugation types. |
VAPB Antibody |
|||
E19-7303 | EnoGene | 100μg/100μl | EUR 225 |
Description: Available in various conjugation types. |
VAPA Antibody |
|||
1-CSB-PA025789GA01HU | Cusabio |
|
|
Description: A polyclonal antibody against VAPA. Recognizes VAPA from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC |
VAPB Antibody |
|||
1-CSB-PA025790ESR2HU | Cusabio |
|
|
Description: A polyclonal antibody against VAPB. Recognizes VAPB from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB; Recommended dilution: WB:1:500-1:5000 |
VAPB Antibody |
|||
1-CSB-PA025790GA01HU | Cusabio |
|
|
Description: A polyclonal antibody against VAPB. Recognizes VAPB from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF |
VAPB Antibody |
|||
DF7303 | Affbiotech | 200ul | EUR 420 |
VAPB Antibody |
|||
DF7303-100ul | Affinity Biosciences | 100ul | EUR 280 |
VAPB Antibody |
|||
DF7303-200ul | Affinity Biosciences | 200ul | EUR 350 |
VAPA Antibody |
|||
DF13847 | Affbiotech | 100ul | EUR 420 |
VAPA Antibody |
|||
DF13847-100ul | Affinity Biosciences | 100ul | EUR 280 |
VAPA Antibody |
|||
DF13847-200ul | Affinity Biosciences | 200ul | EUR 350 |
VAPB antibody |
|||
E39-09370 | EnoGene | 100ug/100ul | EUR 225 |
Description: Available in various conjugation types. |
VAPA Antibody |
|||
E94279 | EnoGene | 100μg | EUR 255 |
Description: Available in various conjugation types. |
VAPA Antibody |
|||
E912939 | EnoGene | 100ul | EUR 255 |
Description: Available in various conjugation types. |
VAPB Antibody |
|||
E95363 | EnoGene | 100μg | EUR 255 |
Description: Available in various conjugation types. |
VAPA Antibody |
|||
E307078 | EnoGene | 100ug/200ul | EUR 275 |
Description: Available in various conjugation types. |
VAPA antibody |
|||
70R-13446 | Fitzgerald | 100 ul | EUR 550 |
Description: Affinity purified Rabbit polyclonal VAPA antibody |
VAPA antibody |
|||
70R-21235 | Fitzgerald | 50 ul | EUR 289 |
Description: Rabbit polyclonal VAPA antibody |
VAPB antibody |
|||
70R-21236 | Fitzgerald | 50 ul | EUR 289 |
Description: Rabbit polyclonal VAPB antibody |
VAPA Antibody |
|||
1-CSB-PA575431 | Cusabio |
|
|
Description: A polyclonal antibody against VAPA. Recognizes VAPA from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;ELISA:1:2000-1:5000, WB:1:500-1:2000, IHC:1:25-1:100 |
VAPA Antibody |
|||
1-CSB-PA126671 | Cusabio |
|
|
Description: A polyclonal antibody against VAPA. Recognizes VAPA from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;ELISA:1:1000-1:2000, WB:1:200-1:1000, IHC:1:25-1:100 |
VAPB Antibody |
|||
RQ4371 | NSJ Bioreagents | 100 ug | EUR 356.15 |
Description: Vesicle-associated membrane protein-associated protein B/C is a protein that in humans is encoded by the VAPB gene. The VAPB gene is found on the 20th human chromosome. The protein encoded by this gene is a type IV membrane protein found in plasma and intracellular vesicle membranes. The encoded protein is found as a homodimer and as a heterodimer with VAPA. This protein also can interact with VAMP1 and VAMP2 and may be involved in vesicle trafficking. |
VAP-B / C Antibody |
|||
20-abx141738 | Abbexa |
|
|
anti- VAPA antibody |
|||
FNab09369 | FN Test | 100µg | EUR 658.5 |
Description: Antibody raised against VAPA |
anti- VAPB antibody |
|||
FNab09370 | FN Test | 100µg | EUR 658.5 |
Description: Antibody raised against VAPB |
anti- VAPB antibody |
|||
FNab09371 | FN Test | 100µg | EUR 702 |
Description: Antibody raised against VAPB |
tRNA(fMet)-specific endonuclease VapC (vapC) Antibody |
|||
abx345867-100g | Abbexa | 100 µg | Ask for price |
tRNA(fMet)-specific endonuclease VapC (vapC) Antibody |
|||
abx345867-20g | Abbexa | 20 µg | EUR 250 |
tRNA(fMet)-specific endonuclease VapC (vapC) Antibody |
|||
abx345867-50g | Abbexa | 50 µg | EUR 350 |
VAPB Conjugated Antibody |
|||
C32803 | SAB | 100ul | EUR 476.4 |
VAPA Conjugated Antibody |
|||
C42826 | SAB | 100ul | EUR 476.4 |
VAPA Polyclonal Antibody |
|||
E-AB-17247-120uL | Elabscience Biotech | 120uL | EUR 240 |
Description: Unconjugated |
VAPA Polyclonal Antibody |
|||
E-AB-17247-200uL | Elabscience Biotech | 200uL | EUR 399 |
Description: Unconjugated |
VAPA Polyclonal Antibody |
|||
E-AB-17247-20uL | Elabscience Biotech | 20uL | EUR 73 |
Description: Unconjugated |
VAPA Polyclonal Antibody |
|||
E-AB-17247-60uL | Elabscience Biotech | 60uL | EUR 143 |
Description: Unconjugated |
VAPB Polyclonal Antibody |
|||
E-AB-60927-120uL | Elabscience Biotech | 120uL | EUR 320 |
Description: Unconjugated |
VAPB Polyclonal Antibody |
|||
E-AB-60927-200uL | Elabscience Biotech | 200uL | EUR 530 |
Description: Unconjugated |
VAPB Polyclonal Antibody |
|||
E-AB-60927-60uL | Elabscience Biotech | 60uL | EUR 200 |
Description: Unconjugated |
VAPB Polyclonal Antibody |
|||
E-AB-60927-each | Elabscience Biotech | each | Ask for price |
Description: Unconjugated |
VAPA Polyclonal Antibody |
|||
E-AB-64387-120uL | Elabscience Biotech | 120uL | EUR 320 |
Description: Unconjugated |
VAPA Polyclonal Antibody |
|||
E-AB-64387-200uL | Elabscience Biotech | 200uL | EUR 530 |
Description: Unconjugated |
VAPA Polyclonal Antibody |
|||
E-AB-64387-60uL | Elabscience Biotech | 60uL | EUR 200 |
Description: Unconjugated |
VAPA Polyclonal Antibody |
|||
E-AB-64387-each | Elabscience Biotech | each | Ask for price |
Description: Unconjugated |
OACD08167-1ML - VAPA Antibody |
|||
OACD08167-1ML | Aviva Systems Biology | 1ml | EUR 669 |
OACD08168-1ML - VAPB Antibody |
|||
OACD08168-1ML | Aviva Systems Biology | 1ml | EUR 669 |
OACA06931-50UL - VAPB Antibody |
|||
OACA06931-50UL | Aviva Systems Biology | 50ul | EUR 189 |
VAPA Rabbit Polyclonal Antibody |
|||
53470 | SAB | 100ul | EUR 439 |
Polyclonal VAPB Antibody (Center) |
|||
APR10692G | Leading Biology | 0.1ml | EUR 580.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human VAPB (Center). This antibody is tested and proven to work in the following applications: |
OACD08167-100UL - VAPA Antibody |
|||
OACD08167-100UL | Aviva Systems Biology | 100ul | EUR 199 |
OACD08168-100UL - VAPB Antibody |
|||
OACD08168-100UL | Aviva Systems Biology | 100ul | EUR 199 |
OACA06931-100UL - VAPB Antibody |
|||
OACA06931-100UL | Aviva Systems Biology | 100ul | EUR 230 |
OAAJ07769-100UL - VAPB Antibody |
|||
OAAJ07769-100UL | Aviva Systems Biology | 100uL | EUR 319 |
OAGA00925-100UL - VAPA antibody |
|||
OAGA00925-100UL | Aviva Systems Biology | 100ul | EUR 369 |
VAPB Rabbit Polyclonal Antibody |
|||
E10G32059 | EnoGene | 100 μl | EUR 275 |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
VAPB Rabbit Polyclonal Antibody |
|||
E10G35088 | EnoGene | 100 μl | EUR 275 |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
VAPA Rabbit Polyclonal Antibody |
|||
E10G08965 | EnoGene | 100 μl | EUR 275 |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
VAPA Rabbit Polyclonal Antibody |
|||
E10G01995 | EnoGene | 100 μl | EUR 275 |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
Polyclonal VAPA Antibody(C-term) |
|||
APR10690G | Leading Biology | 0.1ml | EUR 580.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human VAPA (C-term). This antibody is tested and proven to work in the following applications: |
Polyclonal VAPB Antibody (C-term) |
|||
APR10691G | Leading Biology | 0.1ml | EUR 580.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human VAPB (C-term). This antibody is tested and proven to work in the following applications: |
ARP81006_P050-25UL - VAPA Antibody - middle region |
|||
ARP81006_P050-25UL | Aviva Systems Biology | 25ul | EUR 99 |
OAAB18149-400UL - VAPB Antibody - middle region |
|||
OAAB18149-400UL | Aviva Systems Biology | 400ul | EUR 409 |
Monoclonal VAPA Antibody (monoclonal) (M01), Clone: 4C12 |
|||
APR10689G | Leading Biology | 0.1mg | EUR 580.8 |
Description: A Monoclonal antibody against Human VAPA (monoclonal) (M01). The antibodies are raised in mouse and are from clone 4C12. This antibody is applicable in WB and IF |
ARP81006_P050 - VAPA Antibody - middle region (ARP81006_P050) |
|||
ARP81006_P050 | Aviva Systems Biology | 100ul | EUR 389 |
ARP30769_P050-25UL - VAPA Antibody - C-terminal region |
|||
ARP30769_P050-25UL | Aviva Systems Biology | 25ul | EUR 99 |
OAAB14444-400UL - VAPB Antibody - C-terminal region |
|||
OAAB14444-400UL | Aviva Systems Biology | 400ul | EUR 389 |
VAPB mouse monoclonal antibody, clone OTI4D8 (formerly 4D8) |
|||
TA808674 | Origene Technologies GmbH | 100 µl | Ask for price |
VAPB mouse monoclonal antibody, clone OTI4D8 (formerly 4D8) |
|||
TA808674S | Origene Technologies GmbH | 30 µl | Ask for price |
VAPB mouse monoclonal antibody, clone OTI4C8 (formerly 4C8) |
|||
TA808758 | Origene Technologies GmbH | 100 µl | Ask for price |
VAPB mouse monoclonal antibody, clone OTI4C8 (formerly 4C8) |
|||
TA808758S | Origene Technologies GmbH | 30 µl | Ask for price |
VAPA mouse monoclonal antibody, clone OTI1D3 (formerly 1D3) |
|||
TA809018 | Origene Technologies GmbH | 100 µl | Ask for price |
VAPA mouse monoclonal antibody, clone OTI1D3 (formerly 1D3) |
|||
TA809018S | Origene Technologies GmbH | 30 µl | Ask for price |
ARP30769_P050 - VAPA Antibody - C-terminal region (ARP30769_P050) |
|||
ARP30769_P050 | Aviva Systems Biology | 100ul | EUR 389 |
VAPA mouse monoclonal antibody, clone OTI10E10 (formerly 10E10) |
|||
TA809100 | Origene Technologies GmbH | 100 µl | Ask for price |
VAPA mouse monoclonal antibody, clone OTI10E10 (formerly 10E10) |
|||
TA809100S | Origene Technologies GmbH | 30 µl | Ask for price |
NOVATest VAPERON Neutralizing Antibody Rapid Detection Kit (NOVA Test) |
|||
COVNA-503 | Atlas Link Technology | 20 Tests | Ask for price |
Vesicle Associated Membrane Protein Associated Protein A (VAPA) Antibody |
|||
20-abx104662 | Abbexa |
|
|
Vesicle Associated Membrane Protein Associated Protein B (VAPB) Antibody |
|||
20-abx128303 | Abbexa |
|
|
Vesicle Associated Membrane Protein Associated Protein A (VAPA) Antibody |
|||
20-abx213998 | Abbexa |
|
|
Vesicle Associated Membrane Protein Associated Protein A (VAPA) Antibody |
|||
20-abx241846 | Abbexa |
|
|
Vesicle Associated Membrane Protein Associated Protein A (VAPA) Antibody |
|||
abx104662-100g | Abbexa | 100 µg | EUR 750 |
Vesicle Associated Membrane Protein Associated Protein A (VAPA) Antibody |
|||
abx104662-20g | Abbexa | 20 µg | EUR 275 |
Vesicle Associated Membrane Protein Associated Protein A (VAPA) Antibody |
|||
abx104662-50g | Abbexa | 50 µg | EUR 337.5 |
Vesicle Associated Membrane Protein Associated Protein B (VAPB) Antibody |
|||
abx128303-100l | Abbexa | 100 µl | EUR 275 |
Vesicle Associated Membrane Protein Associated Protein B (VAPB) Antibody |
|||
abx128303-1ml | Abbexa | 1 ml | EUR 750 |
Vesicle Associated Membrane Protein Associated Protein B (VAPB) Antibody |
|||
abx128303-200l | Abbexa | 200 µl | EUR 337.5 |
Vesicle Associated Membrane Protein Associated Protein A (VAPA) Antibody |
|||
abx213998-100l | Abbexa | 100 µl | EUR 250 |
Vesicle Associated Membrane Protein Associated Protein A (VAPA) Antibody |
|||
abx241846-96tests | Abbexa | 96 tests | EUR 250 |
Vesicle-Associated Membrane Protein-Associated Protein A (VAPA) Antibody |
|||
20-abx116587 | Abbexa |
|
|
Vesicle-Associated Membrane Protein-Associated Protein A (VAPA) Antibody |
|||
abx031028-400ul | Abbexa | 400 ul | EUR 627.6 |
Vesicle-Associated Membrane Protein-Associated Protein A (VAPA) Antibody |
|||
abx031028-80l | Abbexa | 80 µl | EUR 343.2 |
Vesicle-Associated Membrane Protein-Associated Protein A (VAPA) Antibody |
|||
abx036154-100ug | Abbexa | 100 ug | EUR 469.2 |
Vesicle-Associated Membrane Protein-Associated Protein A (VAPA) Antibody |
|||
20-abx003175 | Abbexa |
|
|
Vesicle-Associated Membrane Protein-Associated Protein A (VAPA) Antibody |
|||
abx239369-100ug | Abbexa | 100 ug | EUR 610.8 |
Vesicle-Associated Membrane Protein-Associated Protein A (VAPA) Antibody |
|||
abx116587-100g | Abbexa | 100 µg | EUR 612.5 |
Vesicle-Associated Membrane Protein-Associated Protein A (VAPA) Antibody |
|||
abx036154-100g | Abbexa | 100 µg | EUR 337.5 |
The HRT considerably affected nitrogen and phosphorus uptakes together with lipid and starch accumulations by microalgae in harvested biofilms. Domination of nitrogen elimination in 2-day HRT with increased lipid accumulation (20% on dried weight foundation) and phosphorus elimination in 6-day HRT with increased starch manufacturing (27% on dried weight foundation) was noticed by evaluating the performances of the RABRs in duplicate runs.